Sumatriptan FDA Alerts
The FDA Alerts below may be specifically about sumatriptan or relate to a group or class of drugs which include sumatriptan.
MedWatch Safety Alerts are distributed by the FDA and published by Drugs.com. Following is a list of possible medication recalls, market withdrawals, alerts and warnings.
Recent FDA Alerts for sumatriptan
5-Hydroxytryptamine Receptor Agonists (Triptans) - Serotonin Syndrome[Posted 07/19/2006] FDA notified healthcare professionals and consumers of new safety information regarding taking medications used to treat migraine headaches (triptans) together with certain types of antidepressant and mood disorder medications (selective serotonin reuptake inhibitors (SSRIs) and selective serotonin/norepinephrine reuptake inhibitors (SNRIs). A life-threatening condition called serotonin syndrome may occur when triptans are used together with a SSRI or a SNRI.
Serotonin syndrome occurs when the body has too much of a chemical found in the nervous system (serotonin). Each of the above medications (triptans, SSRIs, and SNRIs), cause an increase in serotonin levels. Symptoms of serotonin syndrome may include restlessness, hallucinations, loss of coordination, fast heart beat, rapid changes in blood pressure, increased body temperature, overactive reflexes, nausea, vomiting, and diarrhea.
Healthcare professionals prescribing a triptan, SSRI or SNRI should keep in mind that triptans are often used intermittently and either the triptan, SSRI or SNRI may be prescribed by a different physician; weigh the potential risk of serotonin syndrome with the expected benefit of using the above combination; discuss the possibility of serotonin syndrome with patients if a triptan and an SSRI or SNRI will be used together; and follow patients closely during treatment if a triptan and an SSRI or SNRI are used together.
Patients taking a triptan along with an SSRI or SNRI should talk to their doctor before stopping their medication and should immediately seek medical attention if they experience any of the above symptoms. FDA requested that all manufacturers of triptans, SSRIs and SNRIs update their prescribing information to warn of the possibility of serotonin syndrome when these medications are taken together.
[July 19, 2006]
More sumatriptan Resources
- SUMAtriptan Succinate Syringe injection Consumer Information
- Sumatriptan injection Consumer Information
- Sumatriptan oral/nasal Consumer Information
- Sumatriptan Advanced Consumer Information
- Sumatriptan Nasal, Oral, Subcutaneous Advanced Consumer Information
- Sumatriptan Subcutaneous Advanced Consumer Information
- Sumatriptan Transdermal Advanced Consumer Information
- Sumatriptan AHFS DI Monograph
- Sumatriptan Tablets Consumer Information
- Sumatriptan Nasal Powder Consumer Information
- Sumatriptan Nasal Spray Consumer Information
- Imitrex Injection Prescribing Information
- Imitrex Nasal Spray Prescribing Information
- Sumatriptan Prescribing Information
- Sumatriptan Injection Prescribing Information
- Sumatriptan Nasal Spray Prescribing Information
- SUMAtriptan A-Z Drug Facts